Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -555K | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -16M | -24M | -27M | -34M |
| EBITDA | -15M | -14M | -16M | -22M | -30M |
| Net Income | -27M | -14M | -18M | -24M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.83
-4.25% today
1Y Change
-83.36%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quantum BioPharma Ltd. (QNTM) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $3.83 and down 83.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.1%, free cash flow -21.9% with operating margin 0.0% and ROIC -220.0%. Stock Foundry combines QNTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QNTM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QNTM Max Drawdown
-92.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QNTM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$35.3M
-49.5% YoY
Free Cash Flow
-$21.2M
+26.0% YoY
Revenue Growth
+0.0%
EPS Growth
+35.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -555K | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -16M | -24M | -27M | -34M |
| EBITDA | -15M | -14M | -16M | -22M | -30M |
| Net Income | -27M | -14M | -18M | -24M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 6M | 3M | 17M | 35M |
| Total Assets | 11M | 17M | 17M | 38M | 63M |
| Total Liabilities | 6M | 7M | 5M | 8M | 9M |
| Shareholder Equity | 7M | 11M | 13M | 31M | 54M |
| Total Debt | 2M | 825K | 339K | 516K | 556K |
| Net Debt | -29K | -5M | -2M | -16M | -35M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21M
+26.8% YoY
Capital Expenditures
500K
-37.4% YoY
Free Cash Flow
21M
+26.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-418.5%
Debt / Equity
0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.